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 Abstract 
Purpose: To determine the potential use of water-soluble anionic and cationic carbosilane 
dendrimers (Generations 1-3) as mucoadhesive polymers in eyedrop formulations. Methods: 
Cationic carbosilane dendrimers decorated with ammonium –NH3
+ groups were prepared by 
hydrosylilation of Boc-protected allylamine and followed by deprotection with HCl. Anionic 
carbosilane dendrimers with terminal carboxylate groups were also employed in this study. In 
vitro and in vivo tolerance studies were performed in human ocular epithelial cell lines and rabbit 
eyes respectively. The interaction of dendrimers with transmembrane ocular mucins was 
evaluated with a surface biosensor. As proof of concept, the hypotensive effect of a carbosilane 
dendrimer eyedrop formulation containing acetazolamide (ACZ), a poorly water-soluble drug 
with limited ocular penetration, was tested after instillation in normotensive rabbits. Results: 
The methodology used to synthesize cationic dendrimers avoids the difficulty of obtaining 
neutral –NH2 dendrimers that require harsher reaction conditions and also present high 
aggregation tendency. Tolerance studies demonstrated that both prototypes of water-soluble 
anionic and cationic carbosilane dendrimers were well tolerated in a range of concentrations 
between 5 and 10 µM. Permanent interactions between cationic carbosilane dendrimers and 
ocular mucins were observed using biosensor assays, predominantly for the generation-three 
(G3) dendrimer. An eyedrop formulation containing G3 cationic carbosilane dendrimers (5 µM) 
and ACZ (0.07%) (289.4 mOsm; 5.6 pH; 41.7 mN/m) induced a rapid (onset time 1 h) and 
extended (up to 7 h) hypotensive effect, and led to a significant increment in the efficacy 
determined by AUC0
8h
 and maximal intraocular pressure reduction. Conclusion: This work takes 
advantage of the high-affinity interaction between cationic carbosilane dendrimers and ocular 
transmembrane mucins, as well as the tensioactive behavior observed for these polymers. Our 
results indicate that low amounts of cationic carbosilane dendrimers are well tolerated and able 
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 to improve the hypotensive effect of an acetazolamide solution. Our results suggest that 
carbosilane dendrimers can be used in a safe range of concentrations to enhance the 
bioavailability of drugs topically administered in the eye.  
 
Keywords: Carbosilane dendrimers; ocular transmembrane mucins; mucoadhesion; surface 
plasmon resonance (SPR); hypotensive activity. 
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 Introduction  
It is estimated that only about 5% of any drug administered by the topical ocular route is able to cross 
the cornea, reaching the anterior segment of the eye.1 This makes it necessary to administer multiple 
doses of the drug per day. Furthermore, a portion of some administered drugs can be absorbed through the 
nasal and oral mucosa following drainage through the naso-lacrimal duct, and this can result in systemic 
side effects. One approach to increase ocular drug bioavailability is to maintain the formulation on the 
ocular surface longer. Classic (linear) bioadhesive polymers such as hyaluronic acid or cellulose 
derivatives included in eyedrop formulations can increase the drug residence time on the ocular surface. 
With this strategy, both the systemic drug side effects and the dosing frequency can be reduced.2,3 
However, discomfort, blurred vision, and the presence of residual material around the eye are typically 
associated to these viscous media. 
Recently, the use of dendritic structures has been explored with the aim of increasing the residence 
time of drugs on the ocular surface and reducing systemic absorption. For example, several authors have 
shown that polyamidoamine (PAMAM) dendrimers in solution4 or combined with polyethylene glycol as 
hydrogels5 can improve the residence time of several drugs. These dendritic structures can strongly 
interact with transmembrane ocular mucins, as recently demonstrated by our research group.6  
The approach presented in this work uses new dendritic structures based on a C-Si backbone 
(carbosilane dendrimers) as potential bioadhesive polymers to be included in eyedrop formulations. These 
structures could benefit the administration of very poorly water-soluble drugs on the ocular surface. 
However, the higher hydrophobicity of carbosilane dendrimers implies that it is necessary to introduce 
ionic moieties (anionic or cationic groups) to achieve solubility in water.7-9 The objective of the present 
work is the evaluation of Generations 1, 2, and 3 of carbosilane dendrimers, with both anionic and 
cationic terminal groups, for topical ocular delivery. In an attempt to select the optimal concentration of 
these structures suitable for eye tissues, we first estimated the in vitro and in vivo tolerance in human 
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 conjunctival and corneal cell lines and in rabbit eyes. Afterwards, the interaction of carbosilane 
dendrimers with transmembrane ocular mucin isolates was evaluated by surface plasmon resonance 
(SPR) spectroscopy.6 The most promising candidate was formulated with acetazolamide (ACZ), a 
hypotensive drug useful in glaucoma treatment after oral administration but which is inadequate for 
topical application due to low bioavailability after instillation. The eyedrop formulation was characterized 
and tested in normotensive rabbits.  
Materials and Methods 
Materials 
We prepared anionic dendrimers GnSi(CO2
-, Na+)m (n = 1, m = 8; n = 2, m = 16; n = 3, m = 32) as 
previously published.9 t-butyl N-allylcarbamate (C3H5NHBoc, Boc protected allylamine), Karstedt’s 
catalyst, and HCl (Et2O) were purchased from Sigma Chemical Co. (Madrid, Spain) and used as received.  
A telomerase-immortalized, human corneal-limbal epithelial cell line (HCLE) was kindly supplied by 
Prof. I. K. Gipson (Schepens Eye Research Institute, Boston, MA, USA), and the human conjunctival 
epithelial cell line (IOBA-NHC) was provided by IOBA (Instituto de Oftalmología y Biologia Aplicada, 
Valladolid, Spain). Reagents for cell cultures were purchased from Gibco® (Life Technologies, 
Barcelona, Spain). Acetazolamide, sodium chloride, and 3-(4,5-dimethylthiazol-2-Yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (5 mg/mL in phosphate-buffered saline) were obtained from 
Sigma Chemical Co. (Madrid, Spain). Reagents and materials used for the SPR experiments were 
obtained from GE Healthcare (Orsay, France). All other chemicals used were reagent grade and used as 
received. 
 
Animals 
Male New Zealand white rabbits (San Bernardo Farm, Navarra, Spain), weighing 3-3.5 kg, were used 
for some experiments. The animals were kept in individual cages with free access to food and water. They 
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 were housed in a room with controlled 12h/12h light/dark cycles and maintained at 22ºC with 50% 
relative humidity. All of the protocols herein complied with the ARVO Statement for the Use of Animals 
in Ophthalmology and Vision Research and also are in accordance with the European Communities 
Council Directive (86/609/EEC). 
Methods 
Cationic dendrimers: preparation and characterization 
All reactions were carried out under an inert atmosphere, and solvents were purified from appropriate 
drying agents when necessary. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian 
Unity VXR-300 (300.13 (1H), 75.47 (13C) MHz) or on a Bruker AV400 (400.13 (1H), 100.60 (13C), 79.49 
(29Si) MHz). Chemical shifts (δ) were recorded in parts per million (ppm). 1H and 13C resonances were 
measured relative to internal deuterated solvent peaks considering TMS = 0 ppm. 29Si resonances were 
measured relative to external TMS. When necessary, assignment of resonances was done from HSQC, 
HMBC, COSY, TOCSY, and NOESY NMR experiments. Elemental analyses were performed on a 
LECO CHNS-932 instrument. Mass Spectra were obtained from Bruker Ultraflex III and Agilent 6210  
instruments. Starting dendrimers were GnO3(SiH)m (n = 1, m = 6; n = 2, m = 12; n = 3, m = 24)
 10.  
The synthesis of cationic dendrimers is presented in Scheme 1. 
 
Scheme 1. Synthesis of cationic dendrimers GnO3(NH3
+)m (Compounds 4-6). (i) C3H5NHBoc, [Pt], 
60 ºC, 14 h; (ii) HCl (Et2O). 
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 G1O3(NHBoc)6 (Compound 1) A solution of G1O3(SiH)6 (0.500 g, 0.486 mmol), C3H5NHBoc (0.466 
g, 2.966 mmol) and Karstedt’s catalyst (3% mol of Si-H bonds) were stirred in dry THF (5 mL) in a 
Teflon-valved ampoule and heated at 50 ºC for 16 h. Compound 1 was purified by size exclusion 
chromatography in THF. After removal of the solvent, Compound 1 was obtained as a pale yellow oil 
(0.681 g, 71%). For Compound 1, the NMR data (δ, CDCl3) was as follows: 
1H: -0.09 (s, 9 H, MeSi), -
0.07 (s, 36 H, Me2Si), 0.46 (m, 12 H, SiCH2), 0.53 (m, 30 H, SiCH2), 1.25 (m, 18 H, CH2), 1.42 (m, 12 + 
54 H, CH2 and t-Bu), 1.75 (m, 6 H, OCH2CH2), 3.05 (m, 12 H, CH2N), 3.87 (t, J = 6.3 Hz, 6 H, OCH2), 
4.56 (bs, 6 H, NH), 6.04 (s, 3 H, C6H3); 
13C-{1H}: -5.1 (MeSi), -3.4 (Me2Si), 12.4 (NCH2CH2CH2), 13.8 
(SiCH2), 18.4, 18.6, 20.0 (CH2), 20.5 (OCH2CH2CH2), 24.6 (CH2CH2N), 28.4 (CMe3), 33.2 (OCH2CH2), 
43.8 (NCH2), 67.6 (OCH2), 78.9 (CMe3), 93.7 (C6H3 (CH), 155.9 (NHCO2), 160.9 (i-C6H3); 
29Si: 1.8 
(MeSi), 2.1 (Me2Si). MS-ESI: 1988.3707 [M+NH4]
+. Elemental analysis for C99H204N6O15Si9: Calcd. C, 
60.31; H, 10.43; N, 4.26; Obt. C, 60.78; H, 10.72; N, 4.11.  
G2O3(NHBoc)12 (Compound 2)  Following the above procedure, starting from G2O3(SiH)12 (0.450 g, 
0.210 mmol), C3H5NHBoc (0.400 g, 2.536 mmol), and Karstedt’s catalyst, but washing with n-hexane 
after removal of volatiles, compound 2 was obtained as a pale yellow oil (0.668 g, 79%). For Compound 
2, the NMR (δ, CDCl3) was as follows: 
1H: -0.11 (s, 27 H, MeSi), -0.07 (s, 72 H, Me2Si), 0.43 (m, 26 H, 
CH2Si), 0.53 (m, 72 H, CH2Si), 1.27 (s, 24 H, CH2), 1.42 (m, 24 + 108 H, CH2 and t-Bu), 1.77 (m, 6 H, 
OCH2CH2), 3.05 (m, 24 H, CH2N), 3.86 (m, 6 H, OCH2), 4.59 (bs, 12 H, NH), 6.04 (s, 3 H, C6H3); 
13C-
{1H}: -4.9(MeSi), -4.7 (MeSi), -3.3 (Me2Si), 12.3 (SiCH2), 13.8 (SiCH2), 18.4, 18.6, 18.8, 20.0, 20.1 
(CH2), 20.6 (OCH2CH2CH2), 24.6 (CH2CH2N), 28.4 (CMe3), 33.3 (OCH2CH2), 43.6 (NCH2), 67.6 
(OCH2), 78.9 (CMe3), 93.7 (C6H3 (CH), 155.8 (NHCO2), 160.9 (i-C6H3); 
29Si: 0.9 (MeSi), 1.8 (MeSi), 2.0 
(Me2Si). Elemental Analysis for C201H426N12O27Si21: Calcd. C, 59.85; H, 10.65; N, 4.17; Obt. C, 60.15; H, 
10.99; N, 4.03. 
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 G3O3(NHBoc)24 (Compound 3)  Following the procedure described for Compound 2, starting from 
G3O3(SiH)24 (0.450 g, 0.103 mmol), C3H5NHBoc (0.390 g, 2.474 mmol), and Karstedt’s catalyst, 
Compound 3 was obtained as a pale yellow oil (0.728 g, 87%). For G3, the NMR (δ, CDCl3) data were as 
follows: 1H: -0.11 (s, 54 H, MeSi), -0.07 (s, 144 H, Me2Si), 0.45 (m, 48 H, SiCH2), 0.52 (m, 174 H, 
SiCH2), 1.27 (s, 48 H, CH2), 1.42 (m, 48 + 216 H, CH2 and t-Bu), 1.77 (m, 6 H, OCH2CH2), 3.05 (m, 24 
H, CH2N), 3.84 (m, 6 H, OCH2), 4.63 (bs, 12 H, NH), 6.01 (s, 3 H, C6H3); 
13C-{1H}: -4.9 (MeSi), -3.3 
(Me2Si), 12.8 (CH2CH2CH2N), 14.1 (SiCH2), 17.9-20.6 (CH2), 24.6 (CH2CH2N), 28.4 (CMe3), 33.4 
(OCH2CH2), 43.8 (CH2N), 67.8 (OCH2), 78.9 (CMe3), 93.7 (C6H3 (CH), 155.9 (NHCO2), 160.9 (i-C6H3); 
29Si: 0.9 (MeSi), 1.8 (MeSi), 2.1 (Me2Si). Elemental Analysis for C405H870N24O51Si45: Calc. C, 59.63; H, 
10.75; N, 4.12; Obt. C, 59.00; H, 10.38; N, 3.09. 
G1O3(NH3Cl)6 (Compound 4)  A solution of Compound 1 (0.200 g, 0.100 mmol) in THF (10 mL) 
was treated with HCl (6.0 mL, 1 M in Et2O) and stirred for 1 h. Afterward, the solution was filtered off 
and the residue was washed with Et2O (2 x 25 mL) and dried, obtaining Compound 4 as a white solid 
(0.136 g, 85%). For Compound 4, the NMR (δ, D2O) data were as follows: 
1H: -0.21 (s, 9 H, MeSi), -0.11 
(s, 36 H, Me2Si), 0.44 (s, 42 H, CH2Si), 1.24 (s, 18 H, CH2), 1.55 (s, 12 H, CH2), OCH2CH2 not observed, 
2.80 (s, 12 H, CH2N), 3.55 (bs, 6 H, OCH2), 5.69 (bs, 3 H, C6H3); 
13C-{1H}: -5.4 (MeSi), -3.9 (Me2Si), 
11.1 (NCH2CH2CH2), 12.9 (SiCH2), 18.4, 18.6, 20.0, 21.1 (CH2), 22.1 (OCH2CH2CH2), 31.9 
(OCH2CH2), 48.0 (NCH2), 66.6 (OCH2), 93.1 (C6H3 (CH), 160.0 (i-C6H3); 
29Si: 1.9 (MeSi), 2.2 (Me2Si). 
Elemental Analysis for C69H162Cl6N6O3Si9: Calc. C, 52.14; H, 10.27; N, 5.29; Obt. C, 53.01; H, 10.91; N, 
5.10. 
G2O3(NH3Cl)12 (Compound 5)  Following the above procedure, starting from Compound 2 (0.200 g, 
0.050 mmol) and HCl (12.0 mL, 1 M in Et2O) and stirring for 2 h, Compound 5 was obtained as a white 
solid (0.132 g, 82%). For Compound 5, the NMR (δ, D2O) data were as follows: 
1H: -0.18 (s, 99 H, MeSi 
and Me2Si), 0.44 (s, 102 H, CH2Si), 1.24 (s, 72 H, CH2), 1.55 (s, 24 H, CH2), OCH2CH2 not observed, 
Page 9 of 40
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 2.81 (s, 24 H, CH2N), 3.55 (bs, 6 H, OCH2), 5.69 (bs, 3 H, C6H3); 
13C-{1H}: -5.4 (MeSi), -3.9 (Me2Si), 
11.2 (NCH2CH2CH2), 12.9 (SiCH2), 17.7, 18.8, 21.1 (CH2), 22.1 (OCH2CH2CH2), 31.5 (OCH2CH2), 48.0 
(NCH2), 66.6 (OCH2), 93.1 (C6H3 (CH), 159.8 (i-C6H3); 
29Si: 1.0 and 1.7 (MeSi), 2.1 (Me2Si). Elemental 
Analysis for C141H342Cl12N12O3Si21: Calc. C, 51.80; H, 10.54; N, 5.14; Obt. C, 51.21; H, 10.17; N, 4.83. 
G3O3(NH3Cl)24 (Compound 6). Following the above procedure, starting from Compound 3 (0.200 g, 
0.024 mmol) and HCl (12.0 mL, 1 M in Et2O) and stirring for 2 h, Compound 6 was obtained as a white 
solid (0.134 g, 83%). For Compound 6, the NMR (δ, D2O) data were as follows: 
1H: -0.16 (s, 63 H, 
MeSi), and Me2Si), 0.49 (bm, 270 H, CH2Si), 1.29 (s, 138 H, CH2), 1.55 (s, 48 H, CH2), OCH2CH2 not 
observed, 2.86 (s, 48 H, CH2N), OCH2 not observed, C6H3 not observed; 
13C-{1H}: -4.4 (MeSi), -3.0 
(Me2Si), 12.2 (NCH2CH2CH2), 18.0-18.8, 19.9 (CH2), OCH2CH2CH2 not observed, OCH2CH2 not 
observed, 48.0 (NCH2), OCH2 not observed, C6H3 not observed, i-C6H3 not observed; 
29Si: 1.1 (MeSi), 
2.1 (Me2Si). Elemental Analysis for C285H702Cl24N24O3Si45: Calc. C, 51.63; H, 10.67; N, 5.07; Obt. C, 
51.01; H, 10.12; N, 4.67. 
Carbosilane dendrimers of Generations 1 to 3, both anionic and cationic, were dissolved in NaCl 
0.9% media prior to characterization. For simplicity, the nomenclature employed for dendrimers 
described in the remainder of this paper will be of the type “Gn-A” (for anionic dendrimers) or “Gn-C” 
(for cationic dendrimers), where “Gn” indicates the generation. 
Tolerance studies  
In vitro experiments The cytotoxicity of saline solutions of C-Si anionic and cationic dendrimers G1-3 
was assessed by the mitochondrial-dependent reduction of the tetrazolium salt (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to formazan (MTT method) according to previous works.3 The 
cytotoxicity studies were performed on immortalized human corneal-limbal epithelial (HCLE) cells, 
generously donated by Dr. Ilene K. Gipson (Schepens Eye Research Institute, Harvard Medical School, 
Page 10 of 40
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Boston, MA, USA) and normal human conjunctiva (IOBA-NHC) cells generously donated by the 
Institute for Applied Ophthalmobiology (University of Valladolid, Valladolid, Spain).  
HCLE cells and IOBA cells were seeded into 96-well culture plates (40,000 cells/well) and cultured 
at 37ºC for 24 h in a 5% CO2 atmosphere. Adherent cells were exposed to dendrimer solutions for 15 min 
(short-term), 1 h (intermediate-term), or 4 h (long-term). These times were chosen to emulate the types of 
dwell times on the ocular surface of various formulations. An isotonic NaCl solution with 0.005% 
benzalkonium chloride was used as a positive control. 
Cell viability was determined by the mitochondrial reduction of MTT to formazan. The cells were 
incubated in a MTT solution (5 mg/mL in phosphate-buffered saline) for 3 h at 37 ºC. After careful 
aspiration of the MTT solution, the cells were solubilized with dimethyl sulfoxide (100 µL/well). The 
extent of the reduction of MTT to formazan by the cells was quantified by optical density measurements 
at 550 nm using a plate reader (Digiscan mod 6010152EU, Eugendorf, Austria). Viability was set as 
100% in untreated cells. Eight wells per sample were tested, and the assays were performed in triplicate. 
The results were expressed as the reduction in cellular viability compared to negative controls for at least 
three independent experiments. 
In vivo experiments The in vivo ocular tolerance studies of saline solutions containing C-Si anionic and 
cationic dendrimers G1-3 were performed by instillation of 25 µL of each solution onto the right eye in 
five male New Zealand albino rabbits. The contralateral eye received the same volume of saline solution 
(control). Examination of the eyes was performed by specular microscopy before instillation of any 
substance, just after instillation, and at two and six hours post-instillation. A slit lamp (SL-8Z, Topcon, 
Barcelona, Spain) was used to evaluate pupillary reflex, pupil size, superior and inferior eyelids, presence 
of redness, blepharitis and blepharospasm, tear charge, exudates, fluorescein tear film break up time 
(TBUT), redness of bulbar, limbal and tarsal conjunctival surfaces, inflammation of nictitating 
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 membrane, and transparency of the cornea.11 Ocular signs were graded using the Efron scale (0 = normal; 
1 = trace; 2 = mild; 3 = moderate; 4 = severe)12  
Mucoadhesion studies  
After the tolerance studies, the interaction of selected concentrations of C-Si anionic and cationic 
dendrimers G1-3 with transmembrane ocular mucins was analyzed by SPR spectroscopy (Biacore® T100 
GE Healthcare, Orsay, France). One substance, the ligand, is attached on the surface of a sensor chip. The 
second product, the analyte, is then pumped across the surface via a microfluidic system. If interaction 
between the ligand and the analyte occurs, the refractive index at the surface of the chip changes and is 
registered “on line” as an increase in signal.  
Mucin isolation The isolation of transmembrane mucin from cultured HCLE cells has been 
previously described.6 Briefly, mucin was purified from stratified HCLE cultures by gel chromatography 
on a Sepharose CL-4B size exclusion column. The void volume containing the mucin fraction was 
digested with RNase A and DNase I and further purified by isopycnic density gradient centrifugation in 
cesium chloride. 
Mucin immobilization In a preliminary step, the transmembrane ocular mucin isolates were 
immobilized on the Sia Kit Au chips (Biacore®) by incubation of the chip surface with 50 µL of the 
transmembrane mucin solution isolated as described above (80 µg/mL) overnight at room temperature. 
Afterwards, the chips were intensively rinsed in MilliQ® water. Once each chip was prepared and inserted 
on the Biacore® T100 apparatus, it was again extensively washed with MilliQ® water at 30 µL/min for 12 
h. Resonance units (RU) were measured before and after the immobilization step to monitor the amount 
of mucin attached to the Au chips. Calculations of immobilized mucin amounts were performed on the 
basis of the Biacore® standards where 1 RU = 1 pg/mm2. The optical mucin layer was calculated 
considering that 1 RU corresponds to a resonance angle shift of 10-4 degrees.13  
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 Binding experiments Binding experiments were performed by flowing saline solutions of G1, G2, 
and G3 of C-Si anionic and cationic dendrimers (5 or10 µM) over the mucin coated sensor chip surface 
within the Biacore® T100 apparatus for 300 s at 10 µL/min. After this contact step, the sensorgram (RU 
versus time) was collected until equilibrium was reached using physiological saline solution as the 
running medium control. All studies were performed in triplicate at 35ºC, the physiological ocular surface 
temperature.14 
Results were statistically analyzed by one-way analysis of variance (ANOVA) using SPSS version 
16.0 software. Post-ANOVA analyses were carried out according to the Bonferroni’s multiple 
comparisons test. Results were considered significant when p<0.05. 
Efficacy studies 
Acetazolamide formulations: Preparation and characterization  
Acetazolamide formulations were prepared according to the following procedures:  
Formulation 1 (F1): ACZ 0.07% in saline solution A saturated solution of ACZ was prepared by 
dissolving 3.5 mg of the drug in 5 mL of 0.9% saline. The solution was stirred overnight at 30ºC to ensure 
total dissolution.  
Formulation 2 (F2): ACZ 0.07% in saline solution including 5 µM of G3-C carbosilane 
dendrimer A saturated solution of ACZ was prepared by dissolving 3.5 mg of the drug in 5 mL of 0.9% 
saline containing 5 µM of G3 cationic carbosilane. The solution was stirred overnight at 30ºC to ensure 
total dissolution. 
Both formulations and the saline solution (0.9%) were characterized in terms of surface tension, pH, 
and osmolarity. The pH measurements were performed at room temperature (25°C) with a pH-meter 
(model 230, Mettler, Barcelona, Spain) equipped with a microelectrode (InLab, Mettler). Osmolarity of 
the formulations and vehicle was measured with a Knauer vapor osmometer K-7000 (Knauer GmbH, 
Berlin, Germany). As a reference, a standard 400 mOsm solution of sodium chloride was used. 
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 Determinations were performed at 33-35°C in triplicate. Surface tension of each formulation was 
determined by the Whilelmy plate method (PL21; Krüss, Hamburg, Germany), with a digital tensiometer 
(model K11; Krüss, Hamburg, Germany) in combination with the integrated software (Laboratory 
Desktop software, ver. 3.11; Krüss, Hamburg, Germany) at 33-35ºC. Before each measurement, the 
tensiometer was calibrated with MilliQ® water (72.0 ± 0.5 mN/m). The time required for equilibration of 
the formulations was set to 3 minutes. The formulations were assayed in triplicate, with three 
measurements for each replicate.  
Intraocular pressure measurements 
Intraocular pressure (IOP) was measured with a rebound tonometer (Icare Tonovet; Vantaa, Finland). 
For all of the preparations tested, the instillation volume was 25 µL. Four animal groups were used for 
administration of Formulation 1 (18 right eyes), Formulation 2 (18 right eyes), saline solution 0.9% (10 
right eyes), and saline solution 0.9% containing 5 µM of G3-C cationic carbosilane dendrimer (10 right 
eyes). To study the time-course of the effect of F1 and F2, two IOP measurements were taken before any 
compound was administered (30 minutes and just before the instillation). Then, measurements were taken 
once every hour over a period of 8 hours. 
The effect of each formulation was defined in terms of IOP reduction (∆IOP). It was calculated using 
as reference the IOP basal (%) data determined before any instillation in both eyes for each rabbit. Data 
thus obtained underwent area under the curve-time curve (AUC, %, per hour) analysis according to the 
trapezoidal rule.  
Data were expressed as the means ± standard errors of the mean. Statistical differences between the 
compared values were evaluated by two-tailed student’s t-test. P-values less than 0.05 were considered 
significant.  
For efficacy studies, a comparison of the confidence interval was performed for several activity 
parameters: maximal IOP reduction and area under the curve of the IOP variation versus time plot. 
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 Differences in the efficacy treatment between F1 and F2 were considered significant when the two-sided 
95% confidence interval for the difference between the means of the selected parameters excluded zero.14 
Results 
Carbosilane dendrimers  
Formation of cationic carbosilane dendrimers with –NH3
+ moieties at the periphery can be achieved 
by protonation of neutral primary amine dendrimers.7,10 However, the synthesis of these amine derivatives 
requires harsh reaction conditions, and the amine dendrimers also have a high aggregation tendency, 
making storage and manipulation difficult. Furthermore, allylamine is a highly toxic and volatile liquid. 
For that reason, we used a different approach to obtain cationic carbosilane dendrimers. 
First, neutral dendrimers were prepared with primary amino groups protected with Boc, 
GnO3(NHBoc)m [n = 1, m = 6 (Compound 1); n = 2, m = 12 (Compound 2); n = 3, m = 24 (Compound 3)] 
(Scheme 1). These compounds were obtained by a simple hydrosilylation reaction of commercially 
available C3H5NHBoc. This material is a solid that is clearly lesser toxic than allylamine, and it has 
dendrimers that can be decorated with Si-H terminal bonds following a procedure similar to that 
described for related carbosilane dendrons.15 The neutral dendrimers thus obtained can be easily stored 
even in the absence of solvents. NMR spectroscopy showed the disappearance of resonances 
corresponding to the starting SiMe2H functions and the presence of the new groups. The new alkyl chain-
formed Si(CH2)3N was detected by TOCSY-NMR spectroscopy, observing the three methylene groups as 
multiplets at about 3.0 ppm (CH2N), 1.4 (internal CH2), and 0.5 (CH2Si). By 
13C NMR spectroscopy, 13C 
was found at about 44 ppm. Also, the carbonyl carbon atom was present at about 156 ppm. Finally, in the 
29Si NMR spectra, the outermost silicon atom was present at about 2.3 ppm, whereas the initial SiH 
resonance was observed at about -14 ppm. 
 
Page 15 of 40
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Figure 1:  Drawing of cationic Gn-C (Compounds 4-6) and anionic dendrimers Gn-A used in this work  
 
After formation of the cationic carbosilane dendrimers, deprotection of primary amines was 
successfully performed by addition of excess HCl, isolating the new cationic derivatives GnO3(NH3
+)m [n 
= 1, m = 6 (Compound 4); n = 2, m = 12 (Compound 5); n = 3, m = 24 (Compound 6)] (denoted as G1-C, 
G2-C and G3-C in this paper) (Scheme 1). These derivatives appeared as white solids that were soluble in 
water, DMSO, and MeOH. In these compounds, the main NMR resonance belonged to the CH2N groups, 
observed at about 2.80 ppm in the 1H NMR spectra and at about 48.0 ppm in the 13C NMR spectra. The 
final structures are presented in Figure 1. 
 
In vitro tolerance studies 
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 The exposure of HCLE and IOBA-NHC cultures to the anionic and cationic C-Si dendrimers for 15 
minutes was intended to mimic a single drop administration to the ocular surface. Exposures for 1 and 4 h 
were designed to simulate repeated exposures to the ocular surface.  
 
 
Figure 2: In vitro tolerance of the HCLE and IOBA-NHC cell lines to cationic and anionic C-Si 
dendrimers (Gn-C and Gn-A) in saline solution. White bars, 10 µM; grey bars, 5 µM; n, generation 
number. 
 
All three generations of the anionic dendrimers and generations 1 and 2 of the cationic dendrimers 
were well tolerated at 10 µM (Figure 2). The compounds with percentages of cell survival higher than 
80% relative to non-treated cultures of both cell lines were further evaluated. For the third generation of 
C
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 carbosilane cationic dendrimers, G3-C, it was necessary to reduce the concentration to 5 µM to obtain 
non-toxic solutions. 
In vivo tolerance studies 
At 5 and 10 µM, the evaluated carbosilane dendrimer solutions presented neither discomfort nor 
abnormal clinical signs after topical administration in rabbit eyes (Table 1). The Efron scale scores ranged 
from 0 – 2 in all cases. 
 
Table 1: In vivo tolerance studies in albino rabbit eyes after instillation of 25 µL saline solutions of C-Si dendrimers of 
generation G1, G2, and G3 bearing anionic or cationic surface groups. 
Before instillation 
Preparation Tearing Blepharospasm 
Limbal 
Conjunctiva* 
Tarsal 
Conjunctiva* Cornea* 
G1A (10 µM) No No 1-2 0-1 1 
G2A (10 µM) No No 1-2 0-1 1 
G3A (10 µM) No No 1-2 1 1 
G1C (10 µM) No No 1-2 1 0-1 
G2C (10 µM) No No 1-2 1 0-1 
G3C (5 µM) No No 1 1 0-1 
Saline solution 
(left eyes) 
No No 1-2 1 0-1 
Just after instillation 
Preparation Tearing Blepharospasm 
Limbal 
Conjunctiva* 
Tarsal 
Conjunctiva* Cornea* 
G1A (10 µM) No No 1-2 0-1 1 
G2A (10 µM) N No 1-2 0-1 1 
G3A (10 µM) No No 1-2 1 1 
G1C (10 µM) No Slight 2 1 0-1 
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 G2C (10 µM) No No 2 1 0-1 
G3C (5 µM) No No 1 1 0-1 
Saline solution 
(left eyes) 
No No 1-2 1 0-1 
2h post-instillation 
Preparation Tearing Blepharospasm 
Limbal 
Conjunctiva* 
Tarsal 
Conjunctiva* Cornea* 
G1A (10 µM) No No 1 0-1 1 
G2A (10 µM) No No 1 0-1 1 
G3A (10 µM) No No 1-2 1 1 
G1C (10 µM) No No 0-1 1 0-1 
G2C (10 µM) No No 0-1 1 0-1 
G3C (5 µM) No No 1-2 1 0-1 
Saline solution 
(left eyes) 
No No 1-2 1 0-1 
6h post-instillation 
Preparation Tearing Blepharospasm 
Limbal 
Conjunctiva* 
Tarsal 
Conjunctiva* Cornea* 
G1A (10 µM) No No 1 0-1 0-1 
G2A (10 µM) No No 1 0-1 0-1 
G3A (10 µM) No No 1-2 1 0-1 
G1C (10 µM) No No 1 0-1 0-1 
G2C (10 µM) No No 1 0-1 0-1 
G3C (5 µM) No No 1-2 1 0-1 
Saline solution 
(left eyes) 
No No 1-2 1 0-1 
*, numeric scores based on the Efron scale: 0 = normal;1 = trace; 2 = mild; 3 = moderate; 4 = severe 
 
Interaction of carbosilane dendrimers with transmembrane ocular mucins  
Page 19 of 40
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 The carbosilane dendrimer concentrations used to assess the interaction between the dendrimers and 
transmembrane ocular mucins were the same as used in the in vivo tolerance studies. In these 
experiments, the behaviors of the anionic and cationic dendrimers in contact with ocular mucin were 
completely different from one another. The sensorgram values for the anionic dendrimers returned to 
almost zero after about 350 s, indicating that the interaction between the dendrimers and mucin was non-
permanent (Figure 3a). In contrast, a significant portion of the cationic dendrimers in contact with the 
ocular mucin layer was retained in the glycoprotein layer, permanently modifying the RU signal (Figure 
3b). The highest retention was observed for 5 µM G3-C. 
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 Figure 3: Dendrimer-transmembrane ocular mucin interaction measured by SPR spectroscopy. (a) 
Binding sensorgram of interaction between ocular transmembrane mucin and Generations 1 – 3 of anionic 
carbosilane dendrimers. (b) Binding sensorgram of interaction between ocular transmembrane mucin and 
Generations 1 – 3 of cationic carbosilane dendrimers. (c) Comparison of total cationic and anionic 
dendrimer binding, measured as RU increments, for each of the three generations of Gn-C and Gn-A 
dendrimers. RU, resonance units; SS, saline solution *, p < 0.05 for comparison of cationic dendrimer 
Generation 3 with cationic dendrimer Generations 1 and 2. 
 
Formulation characterization: pH, surface tension, and osmolarity 
Based upon the mucoadhesion studies, the most promising candidate dendrimer was 5 µM G3-C, 
which we then used to prepare the ACZ formulation (drug:polymer ratio 3149:1). The pH, surface 
tension, and osmolarity of the ACZ solution in physiological saline media (0.9%), with and without 
dendrimers (F2 and F1 respectively), were determined (Table 2).  
Table 2: ACZ formulation pH, osmolarity and surface tension.  
ACZ formulation pH Osmolarity (mOsm) Surface tension (mN/m) 
F1 5.6 ± 0.1 294.5 ± 1.5 54.7 ± 0.7 
F2 5.6 ± 0.1 289.4 ± 2.1 41.7 ± 0.2 
F1, 0.07% ACZ in 0.9% NaCl; F2, 0.07% ACZ in a solution of 5 µM G3-C dendrimers and 0.9% NaCl. Data are expressed as 
means ± SEMs (n = 3). 
 
The pH of both F1 and F2 was 5.6±0.1 (Table 2). The osmolarity of the F1 formulation was 294.5±1.5 
mOsm, which was not significantly different from the F2 osmolarity (Table 2). The surface tension of F2 
was significantly lower than F1 (p < 0.05), reflecting moderate tensioactive behavior for G3-C 
dendrimers.  
Page 21 of 40
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Intraocular pressure  
Several activity parameters were selected to evaluate the effect of 5 µM G3-C dendrimer on the 
ACZ-induced hypotension: onset time, peak effect time, maximal IOP reduction (∆IOPmax), effective time 
period, and area under the IOP% versus time curve (AUC0
8h). Neither 0.9% saline (Figure 4a) nor 0.9% 
saline with 5 µM G3-C dendrimer (Figure 4b), both of which served as ACZ-free controls, had a 
hypotensive effect. For F1, composed of 0.07% ACZ in 0.9% saline, the onset of hypotension was evident 
at 2 h post-instillation and lasted for four hours (p < 0.05, Figure 4a). For F2, composed of 0.07% ACZ in 
0.9% saline containing 5 µM G3-C dendrimer, the hypotensive onset was evident at 1 h post-instillation 
and lasted for 7 hours (p < 0.05, Figure 4b). Furthermore, the presence of the dendrimer in the 
formulation slightly delayed the maximal ∆IOP effect.  
The maximum hypotensive effect, 22.6%, was reached by F2, and it was significantly greater than 
the value achieved by F1, 17.2% (p = 0.0057, Figure 4c). The AUC0
8h of F1, 72.8% h, was lower than 
that for F2 (p = 0.0137, Figure 4d). The efficacy of the formulations, as measured by the confidence 
intervals of the AUC0
8h
 and the ∆IOPmax, was significantly higher for F2 than F1 (Figure 5).  
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Figure 4: (a) IOP after instillation of 25 µL of F1 composed of 0.07% ACZ in 0.9% saline (black 
squares) or the vehicle composed of 0.9% saline (white squares). (b) IOP after instillation of 25 µL of F2 
composed of 0.07% ACZ in 0.9% saline containing 5 µM G3-C dendrimer (black squares), and the 
vehicle composed of 0.9% saline containing 5 µM 3G-C dendrimer (white squares). (c) Maximal IOP 
reduction (∆IOPmáx, %) induced by F1 and F2. (d) Area under the curve of the ∆IOP(%) versus time (h) 
from 0 to 8 hours (AUC0
8h) induced by F1 and F2.  
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Figure 5: Relationship between the two mean difference test (Student’s t-test) and confidence intervals 
for the difference of the means. Values to the right of zero correspond to a better response to F2 than to 
F1 for both AUC0
8h and ∆IOPmax. F1, 0.07% ACZ in 0.9% saline; F2, 0.07% ACZ in 0.9% saline 
containing 5 µM G3-C dendrimer. 
 
 
Discussion 
Dendrimers offer very attractive features as novel drug nanocarrier systems. These features include a 
controlled and totally known chemical structure and charge as well as the possibility of interaction with 
biological tissues and drugs.16-19 However, their use in ophthalmology remains almost unexplored in 
contrast to other administration routes (oral, intravenous, or transdermal) where extensive progress has 
been achieved.20,21 Only a few authors have explored the potential of dendrimers as drug carriers in 
p=0.006 
p=0.0131 
Student’s t test 95% Confidence Interval 
ΔIOPmax 
AUC0  (%·h) 
8h
 1.09<F2-F1<7.07 
2.12<F2-F1<34.08 
0 F2 demonstrates superiority against F1 
TREATMENT DIFFERENCE 
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 ophthalmology. Vandamme and Brobeck demonstrated that the co-administration of PAMAM dendrimers 
with pilocarpine or tropicamide prolonged and sustained the pharmacological effect of the drugs in 
comparison to classical drug solutions.4 More recently, using surface biosensors we demonstrated a strong 
interaction between PAMAM dendrimers and ocular transmembrane mucins.6 According to these initial 
works, it is worth considering dendrimers as useful tools to increase drug retention time on the ocular 
surface, which in turn could reduce the administration frequency and thus increase patient compliance. 
With this idea, we generated new dendrimers based on a carbosilane structure, and evaluated the 
suitability as eyedrop excipients. The carbosilane skeleton provides these dendrimers with unique 
advantages. Among them, a simple method for synthesis, chemical inertia of the carbon-carbon and 
carbon-silicon bonds that prevent secondary reactions, and importantly, a highly hydrophobic character 
that allows better interaction of the dendrimer with biological membranes and/or hydrophobic drugs. 
Because this was the first time that these structures have been evaluated for ocular administration, we 
performed tolerance studies to determine the suitable concentration for ocular tissues. The initial in vitro 
tolerance assay with human ocular cell lines showed higher toxicity for the cationic dendrimers than for 
the anionic ones. These results are in concordance with other cytotoxicity studies performed in different 
cell lines.22,23 Some authors have attributed the cytotoxicity of cationic dendrimers to the high density of 
positive charges that increases with each generation of dendrimer and that could disrupt the cell 
membranes.24-26 Nevertheless, several studies have demonstrated that cationic dendrimers have the same 
or lower toxicity than polycationic linear polymers.26-28 Indeed, Vandamme and Brobeck, for example, 
observed better tolerance results for PAMAM dendrimers than for linear polymers (hydroxypropylmethyl 
cellulose and Carbopol®) on the ocular surface.4 Furthermore, Bermejo and co-workers evaluated the 
biocompatibility of carbosilane dendrimers in primary cell cultures of peripheral blood mononuclear cells 
and erythrocytes and found they had good toxicity profiles over extended periods of time.7 Based upon 
our in vitro tolerance studies, we administered anionic and cationic carbosilane dendrimer solutions to the 
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 ocular surface of rabbit eyes and found no alterations or discomfort. This further confirmed that the 
polymer concentrations selected in the in vitro study were suitable for ocular administration in animals. 
We next determined the possible interaction of carbosilane dendrimers with elements of the ocular 
surface, specifically with corneal transmembrane mucins. These high molecular weight glycoproteins 
cover the corneal and conjunctival epithelia, anchor the precorneal tear film, and play an essential role in 
mucoadhesion.29 We used surface biosensors with high sensitivity, so only small amounts of ligand and 
analyte were needed.30-32 Because this is the first in vitro method specifically designed to evaluate 
interfacial mucin-polymer interactions, we recently proposed it as a very valuable tool in understanding 
the interactions of ocular transmembrane mucins with polymers or other macromolecules, especially 
when low amounts of mucins are available.6 
The cationic dendrimer G3-C exhibited a significant permanent chemical adherence to the ocular 
transmembrane mucins. This interaction might be governed by electrostatic interactions between primary 
amino groups of the dendrimers and the sialic acid and sulphated groups present in the glycosylated 
chains of the mucins. In a previous work, this technique showed that the anionic dendrimer PAMAM-
COOH permanently interacted with the ocular mucin layer, probably due to the formation of hydrogen 
bonds between charged carboxylic groups of the dendrimer and the sugar residue on the mucins side 
chains.6 However, the anionic carbosilane dendrimers used in the current work had a more hydrophobic 
backbone and non-protonated terminal carboxylate groups compared to PAMAM. Thus the formation of 
such interactions between the anionic carbosilane dendrimers and the mucins was not favored, probably 
because the electrostatic repulsion with the negatively charged mucin surface was strong enough to 
prevent permanent chemical interaction. Due to the lack of mucin interaction, we chose not to pursue the 
anionic dendrimers in further studies. 
ACZ was chosen as the model drug to evaluate the potential of enhancing ocular surface 
bioavailability. This carbonic anhydrase inhibitor has a potent specific effect in reducing aqueous humor 
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 production, and therefore, intraocular pressure. It has high potential in the treatment of glaucoma, in 
which high and persistent IOP promotes damage of the optic disk at the juncture of the optic nerve and 
retina, provoking irreversible retinal degeneration and blindness. However, the use of ACZ is limited 
because it has low bioavailability after ocular instillation due to low aqueous solubility and limited ocular 
penetration. For those same reasons, ACZ has gained attention as a model drug to test different strategies 
to increase bioavailability after ophthalmic application. Some efforts have been explored with this model 
drug, from the classical approach of using drug suspensions in polymeric solutions33 to the use of more 
structured and sophisticated systems such as liposomes,34 cyclodextrin complexes,35,36 niosomes,37 
nanoparticles,38 and commercial poly(propyleneimine) dendrimers.39 In those studies, ACZ efficacy was 
improved; however in some cases, tolerance studies were either not performed or they were unsuitable. 
Consequently, the potential cytotoxicity of the formulations is unknown.  
In this work, we performed the essential in vitro and in vivo tolerance studies that allowed us to select 
an innocuous final prototype for in vivo efficacy studies. pH and osmolarity studies confirmed that the 
behavior of the selected formulation is totally compatible with the ocular surface.40 The very simplistic 
approach explored takes advantage of the high interaction of cationic carbosilane dendrimers with ocular 
transmembrane mucins as well as the tensioactive behavior observed for these polymers. The inclusion of 
a very low amount of cationic carbosilane dendrimer, 5 µM G3-C, in the ACZ solution in saline media 
resulted in a more rapid and extended hypotensive effect, leading to a significant increment in the 
efficacy. The low drug:polymer ratio used in this formulation indicates that most of the drug must not be 
directly attached to the dendrimer structure. Under these conditions, the inclusion of the cationic 
carbosilane dendrimers might promote the formation of a well-spread aqueous eyedrop layer, favored by 
the tensioactive nature of the formulation, that is strongly attached to the ocular surface and that enhances 
the retention of the drug. In contrast to formulations containing linear polymers, this increment in the 
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 retention time would be achieved without modifying the viscosity of the tear film, preventing the 
discomfort typically associated to these viscous media.29 
Conclusions 
The high chemical versatility and the small and controlled size of dendrimers allow the design of 
preparations able to interact with biological molecules, representing a simplified alternative to more 
complex systems for drug administration. In this work, we evaluated the potential use of ionic C-Si 
dendrimers for ocular administration. In vitro and in vivo tolerance studies were performed to select an 
innocuous prototype.  
In this proof of concept, the inclusion of only a very low amount of cationic carbosilane dendrimer 
was well tolerated and improved the hypotensive effect of an ACZ solution by decreasing the onset time 
and increasing the duration after a single instillation. This is the first work demonstrating that carbosilane 
dendrimers can enhance the bioavailability of drugs administered topically in the eye. 
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